Immatics, a biotech company working on promising cell-based immunotherapies for solid cancers, has a promising TCR-engineered ...

Immatics has vaulted into phase 3 on the strength of early-stage data. The biotech is gearing up to start a pivotal trial of ...

Leerink Partners analyst Jonathan Chang reiterated a Buy rating on Immatics (IMTX – Research Report) on October 11 and set a price target ...

Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development ...

On Thursday, Immatics N.V. (NASDAQ:IMTX) stock is trading lower after the company commenced an underwritten public offering ...

We recently published a list of 10 Best Biotech Stocks To Buy Under $20. In this article, we are going to take a look at ...

Immatics shares were down 10% to $9.95 after the company began a proposed $150 million underwritten public offering of its ordinary shares.

German cancer specialist Immatics has priced a $150 million public offering with Jefferies, BofA Securities, and Leerink as ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on IMTX stock, giving a Buy rating on October 7. Graig ...

Piper Sandler started coverage on shares of Immatics (NASDAQ:IMTX – Free Report) in a research report report published on Monday, MarketBeat reports. The firm issued an overweight rating and a $ ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development ...